Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Petr Widimsky,
Clopidogrel pre-treatment before planned PCI was proved to reduce periprocedural complications. However, majority of patients do not undergo planned PCI, but rather "ad-hoc“ PCI performed a few minutes after coronary angiography. Whether clopidogrel should be administered as pre-treatment to all pts undergoing elective coronary angiography with the aim of ensuring therapeutic levels at the time of possible ad-hoc PCI is not known. View the slides 1028 patients undergoing elective coronary angiography were randomized to group A (“nonselective” - clopidogrel 600 mg > 6 hours before CAG; n = 513) or group B (“selective” - clopidogrel 600 mg in the cath-lab after CAG, only to patients undergoing subsequent PCI; n = 515). The combined primary end-point was death / periprocedural myocardial infarction / stroke or transient ischemic attack / re-intervention within 7 days. Secondary end-points were troponin elevation and bleeding complications. The primary end-point occurred in 0.8% in both groups (non significant, NS). Bleeding complications occurred in 3.5% of group A patients vs. 1.2% in group B (p = 0.02). Periprocedural troponin elevation (> 3x ULN) was detected in 2.7% in group A vs. 3.0% in group B (NS). When only the patients who underwent PCI were analyzed, primary end-point occurred in 1.3% in group A vs. 2.2% in group B (NS). Periprocedural troponin elevation was detected in 8.6% (group A) vs. 11.1% (group B, NS). Bleeding complications occurred in 7.2% (group A) vs. 0.7% (group B, p = 0.006).
Routine clopidogrel pretreatment before elective coronary angiography is not justified – it increases the risk of bleeding complications, while the benefit on periprocedural infarction is not significant. Clopidogrel should be given only to patients with known coronary angiography who undergo PCI and this can be done safely in the catheterization laboratory between the two procedures.